Alopecia areata is a chronic, relapsing autoimmune skin disease. JAK inhibitors have transformed the treatment of severe alopecia areata since their approval for this indication in China in 2023, offering a more favorable side-effect profile and more stable hair regrowth than traditional corticosteroids and immunosuppressants. However, high relapse rates after drug withdrawal remain a central clinical challenge: international studies have documented the relapse phenomenon, but practical, evidence-based risk-stratification criteria to guide withdrawal decisions have been lacking.
A research team led by Prof. Ji Li, Prof. Wei Shi, and Associate Prof. Yan Tang of Xiangya Hospital, Central South University, has recently published a prospective real-world cohort study in the Journal of the American Academy of Dermatology (JAAD), titled “Acute-phase disease and super-responder status predict reduced relapse risk after ritlecitinib withdrawal in alopecia areata: A prospective real-world study.” The study reports that acute-phase disease onset and super-responder status may independently reduce relapse risk after withdrawal, providing local evidence to inform long-term disease management of alopecia areata [1].
This article presents in-depth commentary on the study from Prof. Wei Shi and Associate Prof. Yan Tang.
Expert Profile: Prof. Wei Shi
• Chief Physician, Professor, and Doctoral Supervisor, Department of Dermatology, Xiangya Hospital, Central South University
• Visiting Scholar, Department of Pathology, Tulane University, USA; South Carolina Dermatology Group Hospital, USA
• Member, Dermatology Pathology Committee, Chinese Medical Association Dermatology Branch
• Member, Lupus Erythematosus Research Collaboration Group, Chinese Medical Association Dermatology Branch
• Vice Chair, Hair Medicine and Scalp Health Management Committee, Medical Aesthetics Committee, Chinese Association of Integrative Medicine
• Member, Dermatology Pathology Group, Dermatology Branch, Chinese Association of Rehabilitation Medicine
• Member, Dermatology Pathology Group, Dermatology Committee, Chinese Association of Integrative Medicine
• Member, Dermatology Committee, China Alliance for Rare Diseases
• Member, Skin Medicine Expert Committee, Cosmetics Industry Branch, China Association for Anti-Aging Promotion
Expert Profile: Associate Prof. Yan Tang
• PhD, Associate Chief Physician, Associate Research Fellow, and Doctoral Supervisor
• Visiting Scholar, Emory University, USA (2013-2015)
• Member, Mycology Group, Dermatology Branch, Chinese Medical Association
• Member, Dermatology Branch, Chinese Geriatric Health Care Medical Research Association
• Member, Hair Medicine and Scalp Health Management Committee, Skin Professional Committee, Chinese Non-Public Medical Institutions Association
• Vice Group Leader, Hair Group, Dermatology and Venereology Professional Committee, Hunan Province Association of Chinese and Integrative Medicine
• Member, Hair Transplant Group, Medical Aesthetics Committee, Hunan Province Association of Chinese and Integrative Medicine
• Secretary, Dermatologic Surgery Group, Hunan Medical Association
• Research focus: alopecia, rosacea and other cosmetic skin disorders, and dermatologic surgery
• Has published 19 SCI papers as first or corresponding author (including co-first/co-corresponding) in high-impact journals such as Nat Commun and Adv Sci; Principal Investigator of two National Natural Science Foundation of China grants (one Youth, one General) and one Hunan Provincial Natural Science Foundation General Program grant
Clinical Challenge: Established Efficacy, No Standardized Withdrawal Protocol
“JAK inhibitors have allowed many patients with severe alopecia areata to regrow hair, but almost every patient whose hair has regrown asks the same questions: When can I stop the drug? Can I stop taking it?” Prof. Wei Shi opened the interview by addressing one of the most pointed questions in clinical practice.
Compared with traditional corticosteroids and immunosuppressants, JAK inhibitors have a more favorable side-effect profile and more stable hair-regrowth efficacy; however, several persistent challenges remain in clinical practice:
High relapse rate after withdrawal: Among 85 patients who discontinued ritlecitinib in this study, 48.2% experienced relapse, with relapse-free survival rates of 69.5%, 55.7%, and 48.4% at 12, 24, and 48 weeks, respectively.
Strong patient demand to discontinue: Monthly drug costs exceed ¥2,000, creating sustained economic pressure for long-term use. Many patients discontinue the drug on their own once hair has regrown, with poor follow-up adherence and a high risk of relapse.
Lack of evidence-based stratified management: Current guidelines recommend long-term maintenance without risk-stratification criteria, leaving clinicians to rely on experience alone when guiding dose reduction or withdrawal.
Prof. Shi noted that, although traditional understanding of autoimmune diseases suggests that alopecia areata may require lifelong therapy, the economic, fertility-related, and psychological needs of Chinese patients cannot support indefinite medication. “Our core objective is not simply to help patients regrow hair, but to identify approaches that allow long-term maintenance of hair regrowth at the lowest possible drug burden and with the fewest side effects — this is the rationale for launching this prospective cohort study,” Prof. Shi explained.
To this end, the team established a long-term follow-up cohort for severe alopecia areata beginning in 2021 and conducted a prospective real-world study from 2023 to 2025, addressing an evidence gap in this field in China.
Innovative Study Design: Reflecting Real-World Outpatient Practice
The study enrolled 85 patients with alopecia areata who discontinued ritlecitinib after treatment. The median age was 18 years, and 58.8% were female. Acute-phase disease (current episode duration ≤6 months) accounted for 62.4% of patients, and 48.2% met the criteria for super-responder status. The median treatment duration was 28 weeks, and 76.5% of patients had achieved complete hair regrowth by the time of withdrawal. Associate Prof. Yan Tang highlighted two innovative design features that distinguish this study from previous international randomized controlled trials and form the basis for the reliability of the conclusions.
Composite relapse endpoint: Rather than relying on the Severity of Alopecia Tool (SALT) score alone, relapse was defined as meeting any of the following criteria: restart of systemic immunotherapy; SALT score crossing the responder threshold; or an increase of more than 10 points from the patient’s best state. Use of topical minoxidil or steroids during follow-up was not counted as relapse, better reflecting real-world clinical scenarios.
Standardized super-responder definition: Super-responder status was defined as SALT improvement ≥80% within 3 months or SALT100 within 6 months. This definition incorporates the 3-6 month hair growth cycle and aligns with global targeted-therapy clinical data, enabling precise identification of patients highly sensitive to JAK pathway inhibition.
Two Independent Protective Factors That Challenge Conventional Clinical Intuition
Using univariate and multivariate Cox regression models with adjustment for confounding variables, the study identified two factors with independent predictive value — findings that may overturn long-standing clinical intuitions among dermatologists.
1. Acute-Phase Disease Onset: 69% Reduction in Relapse Risk
Acute-phase disease was defined as current episode duration ≤6 months. Multivariate analysis showed that acute-phase patients had an adjusted hazard ratio (HR) of 0.309 (95% CI 0.161-0.591, P<0.001), corresponding to a 69% lower relapse risk compared with patients with chronic disease duration.
This finding supports the “early intervention window” hypothesis in alopecia areata, with mechanistic parallels to early IL-23 inhibitor intervention in psoriasis: within 6 months of disease onset, perifollicular inflammation is still in its early stage and long-lived autoimmune memory cells have not yet formed. Initiating JAK inhibitors during this window may interrupt the inflammatory cascade and prevent permanent immune cell infiltration of hair follicles. In contrast, by the chronic phase, tissue-resident memory T cells have become established, and inflammation is prone to rapid relapse after drug withdrawal.
“Some clinicians have traditionally recommended watchful waiting and conservative topical treatment for mild cases in anticipation of spontaneous resolution, but these data clearly indicate that once moderate-to-severe alopecia areata is diagnosed, early initiation of systemic targeted therapy during the acute phase is a key prerequisite for achieving safe withdrawal,” Associate Prof. Yan Tang added.
2. Super-Responder Status: 58% Reduction in Relapse Risk
Patients meeting the super-responder criteria had an adjusted HR of 0.420 (95% CI 0.215-0.820, P=0.011), corresponding to an independent 58% reduction in relapse risk. In these patients, the immune system is highly sensitive to JAK pathway inhibition, and short-term treatment can fully suppress follicular immune attack. After withdrawal, the body is more likely to maintain immune balance, making this group the most suitable candidates for attempting rapid dose reduction or drug withdrawal in clinical practice.
3. Challenging Conventional Assumptions: Age, Sex, and Treatment Duration Lack Independent Predictive Value
Clinically, it has been widely assumed that younger patients, female patients, and patients with longer treatment duration are less likely to relapse after withdrawal. However, after multivariate adjustment, age, sex, total treatment duration, complete remission, atopic status, and nail involvement showed no independent predictive value.
Prof. Shi emphasized that this finding reflects the core value of real-world cohort studies: “Clinical judgment cannot rely on experiential intuition; it must be grounded in evidence-based data. Even after years of continuous medication, patients with chronic disease duration and without super-responder status remain at high relapse risk after withdrawal. Conversely, acute-phase super-responders may achieve safe dose reduction after a short, standardized course of treatment.”
Risk-Stratified Management: Differentiated Withdrawal Protocols
Prof. Shi noted that the most important value of this study is providing clinicians with a directly applicable, risk-stratified management framework for alopecia areata withdrawal, addressing the limitations of a “one-size-fits-all” approach.
For patients with economic pressure, family-planning needs, or mild drug intolerance, clinicians may have greater confidence to shorten the maintenance period, extend dosing intervals, and reduce doses or withdraw more rapidly. Follow-up frequency may be moderately relaxed, with particular attention to the high-risk relapse window of 12-24 weeks after withdrawal.
For high-relapse-risk patients (those with chronic disease duration or without super-responder status), rapid withdrawal is not recommended. A longer full-dose maintenance period and a gradual stepwise dose-reduction regimen should be adopted, with close follow-up throughout. At the first sign of increased hair shedding or a positive pull test, treatment should be resumed promptly to avoid large-scale relapse.
Drawing on the team’s experience with a multidisciplinary combined clinic, Prof. Shi added that alopecia areata management should not focus solely on pharmacotherapy. The team has collaborated with the Traditional Chinese Medicine and Psychology departments to deliver a combined dermatology-specialty clinic, using TCM regulation and psychological counseling to modulate systemic immune balance and reduce relapse risk. For alopecia areata patients with comorbid anxiety or depression, integrated physical and psychological intervention may substantially improve long-term remission rates.
References:
[1] Huang J, Li M, Li J, Tang Y, Shi W. Acute-phase disease and super-responder status predict reduced relapse risk after ritlecitinib withdrawal in alopecia areata: A prospective real-world study. J Am Acad Dermatol. Published online June 29, 2026. doi:10.1016/j.jaad.2026.06.116